198 related articles for article (PubMed ID: 30784762)
1. Pak1 gene functioned differentially in different BCR-ABL subtypes in leukemiagenesis and treatment response through STAT5 pathway.
Yuanxin Y; Yanhong Z; Qin Z; Sishi T; Yang D; Yi Z; Minjin W; Juan Z; Xiaojun L; Lanlan W; Binwu Y
Leuk Res; 2019 Apr; 79():6-16. PubMed ID: 30784762
[TBL] [Abstract][Full Text] [Related]
2. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
van Rhee F; Hochhaus A; Lin F; Melo JV; Goldman JM; Cross NC
Blood; 1996 Jun; 87(12):5213-7. PubMed ID: 8652835
[TBL] [Abstract][Full Text] [Related]
3. Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets.
Adnan-Awad S; Kim D; Hohtari H; Javarappa KK; Brandstoetter T; Mayer I; Potdar S; Heckman CA; Kytölä S; Porkka K; Doma E; Sexl V; Kankainen M; Mustjoki S
Leukemia; 2021 Jul; 35(7):1964-1975. PubMed ID: 33168949
[TBL] [Abstract][Full Text] [Related]
4. Multiplex in-cell reverse transcription-polymerase chain reaction for the simultaneous detection of p210 and p190 BCR-ABL mRNAs in chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia cell lines.
Suh SP; Kee SJ; Lim WH; Song JW; Lee SK; Kim JP; Shin JH; Ryang DW
Clin Chem Lab Med; 2000 Sep; 38(9):939-44. PubMed ID: 11097354
[TBL] [Abstract][Full Text] [Related]
5. Pre-B acute lymphoblastic leukemia with b3a2 (p210) and e1a2 (p190) BCR-ABL fusion transcripts relapsing as chronic myelogenous leukemia with a less differentiated b3a2 (p210) clone.
Winter SS; Greene JM; McConnell TS; Willman CL
Leukemia; 1999 Dec; 13(12):2007-11. PubMed ID: 10602422
[TBL] [Abstract][Full Text] [Related]
6. Leukemogenesis of b2a2-type p210 BCR/ABL in a bone marrow transplantation mouse model using a lentiviral vector.
Uchida N; Hanawa H; Dan K; Inokuchi K; Shimada T
J Nippon Med Sch; 2009 Jun; 76(3):134-47. PubMed ID: 19602820
[TBL] [Abstract][Full Text] [Related]
7. Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics.
Reckel S; Hamelin R; Georgeon S; Armand F; Jolliet Q; Chiappe D; Moniatte M; Hantschel O
Leukemia; 2017 Jul; 31(7):1502-1512. PubMed ID: 28111465
[TBL] [Abstract][Full Text] [Related]
8. [Sequential analysis of p210- and p190-bcr-abl by RT-PCR after allogeneic bone marrow transplantation for p210/p190-bcr-abl double positive acute lymphoblastic leukemia].
Fujimaki K; Maruta A; Yoshida M; Yamazaki E; Motomura S; Kodama F; Matsuzaki M; Fujisawa S; Kanamori H; Ishigatsubo Y
Rinsho Ketsueki; 2001 Feb; 42(2):89-93. PubMed ID: 11280922
[TBL] [Abstract][Full Text] [Related]
9. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice.
Voncken JW; Kaartinen V; Pattengale PK; Germeraad WT; Groffen J; Heisterkamp N
Blood; 1995 Dec; 86(12):4603-11. PubMed ID: 8541551
[TBL] [Abstract][Full Text] [Related]
10. Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene.
Snyder DS; Wu Y; McMahon R; Yu L; Rossi JJ; Forman SJ
Biol Blood Marrow Transplant; 1997 Oct; 3(4):179-86. PubMed ID: 9360779
[TBL] [Abstract][Full Text] [Related]
11. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
[TBL] [Abstract][Full Text] [Related]
12. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
[TBL] [Abstract][Full Text] [Related]
13. Is p190 bcr-abl rearrangement necessary for acute transformation in some p210 CML of childhood?
Scrideli CA; de Oliveira FM; Brassesco MS; de Paula Queiroz R; Bernardes JE; Valera ET; Tone LG
Leuk Res; 2009 Mar; 33(3):495-9. PubMed ID: 18495245
[TBL] [Abstract][Full Text] [Related]
14. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
He Y; Wertheim JA; Xu L; Miller JP; Karnell FG; Choi JK; Ren R; Pear WS
Blood; 2002 Apr; 99(8):2957-68. PubMed ID: 11929787
[TBL] [Abstract][Full Text] [Related]
15. Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation.
Score J; Calasanz MJ; Ottman O; Pane F; Yeh RF; Sobrinho-Simões MA; Kreil S; Ward D; Hidalgo-Curtis C; Melo JV; Wiemels J; Nadel B; Cross NC; Grand FH
Leukemia; 2010 Oct; 24(10):1742-50. PubMed ID: 20703256
[TBL] [Abstract][Full Text] [Related]
16. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
[TBL] [Abstract][Full Text] [Related]
17. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
[TBL] [Abstract][Full Text] [Related]
18. Invadopodia and rolling-type motility are specific features of highly invasive p190(bcr-abl) leukemic cells.
Daubon T; Rochelle T; Bourmeyster N; Génot E
Eur J Cell Biol; 2012; 91(11-12):978-87. PubMed ID: 22717125
[TBL] [Abstract][Full Text] [Related]
19. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
Gross AW; Ren R
Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
[TBL] [Abstract][Full Text] [Related]
20. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
